Mawia Khairalseed1,2, Kulsoom Javed1, Gadhvi Jashkaran3, Jung-Whan Kim3, Kevin J Parker4, Kenneth Hoyt1,5. 1. Department of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA. 2. Department of Biomedical Engineering, Sudan University of Science and Technology, Khartoum, Sudan. 3. Department of Biological Sciences, University of Texas at Dallas, Richardson, Texas, USA. 4. Department of Electrical and Computer Engineering, University of Rochester, Rochester, New York, USA. 5. Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Abstract
OBJECTIVE: H-scan imaging is a new ultrasound technique used to visualize the relative size of acoustic scatterers. The purpose of this study was to evaluate the use of H-scan ultrasound imaging for monitoring early tumor response to neoadjuvant treatment using a preclinical breast cancer animal model. METHODS: Real-time H-scan ultrasound imaging was implemented on a programmable ultrasound scanner (Vantage 256; Verasonics Inc., Kirkland, WA) equipped with an L11-4v transducer. Bioluminescence and H-scan ultrasound was used to image luciferase-positive breast cancer-bearing mice at baseline and at 24, 48, and 168 hours after administration of a single dose of neoadjuvant (paclitaxel) or sham treatment. Animals were euthanized at 48 or 168 hours, and tumors underwent histologic processing to identify cancer cell proliferation and apoptosis. RESULTS: Baseline H-scan ultrasound images of control and therapy group tumors were comparable, but the latter exhibited significant changes over the 7-day study (P < .05). At termination, there was a marked difference between the H-scan ultrasound images of control and treated tumors (P < .05). Specifically, H-scan ultrasound images of treated tumors were more blue in hue than images obtained from control tumors. There was a significant linear correlation between the predominance of the blue hue found in the H-scan ultrasound images and intratumoral apoptotic activity (R2 > 0.40, P < .04). CONCLUSION: Preliminary preclinical results suggest that H-scan ultrasound imaging is a new and promising tissue characterization modality. H-scan ultrasound imaging may provide prognostic value when monitoring early tumor response to neoadjuvant treatment.
OBJECTIVE: H-scan imaging is a new ultrasound technique used to visualize the relative size of acoustic scatterers. The purpose of this study was to evaluate the use of H-scan ultrasound imaging for monitoring early tumor response to neoadjuvant treatment using a preclinical breast cancer animal model. METHODS: Real-time H-scan ultrasound imaging was implemented on a programmable ultrasound scanner (Vantage 256; Verasonics Inc., Kirkland, WA) equipped with an L11-4v transducer. Bioluminescence and H-scan ultrasound was used to image luciferase-positive breast cancer-bearing mice at baseline and at 24, 48, and 168 hours after administration of a single dose of neoadjuvant (paclitaxel) or sham treatment. Animals were euthanized at 48 or 168 hours, and tumors underwent histologic processing to identify cancer cell proliferation and apoptosis. RESULTS: Baseline H-scan ultrasound images of control and therapy group tumors were comparable, but the latter exhibited significant changes over the 7-day study (P < .05). At termination, there was a marked difference between the H-scan ultrasound images of control and treated tumors (P < .05). Specifically, H-scan ultrasound images of treated tumors were more blue in hue than images obtained from control tumors. There was a significant linear correlation between the predominance of the blue hue found in the H-scan ultrasound images and intratumoral apoptotic activity (R2 > 0.40, P < .04). CONCLUSION: Preliminary preclinical results suggest that H-scan ultrasound imaging is a new and promising tissue characterization modality. H-scan ultrasound imaging may provide prognostic value when monitoring early tumor response to neoadjuvant treatment.
Authors: Chengyue Wu; Angela M Jarrett; Zijian Zhou; Nabil Elshafeey; Beatriz E Adrada; Rosalind P Candelaria; Rania M M Mohamed; Medine Boge; Lei Huo; Jason B White; Debu Tripathy; Vicente Valero; Jennifer K Litton; Clinton Yam; Jong Bum Son; Jingfei Ma; Gaiane M Rauch; Thomas E Yankeelov Journal: Cancer Res Date: 2022-09-16 Impact factor: 13.312
Authors: Jihye Baek; Rifat Ahmed; Jian Ye; Scott A Gerber; Kevin J Parker; Marvin M Doyley Journal: Ultrasound Med Biol Date: 2020-09-06 Impact factor: 3.694